IDXX Stock Cash Flow Statements

IDEXX Laboratories Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Free Cash Flow

Capital Expenditure

IDEXX Laboratories Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31

cash flows from operating activities:
net income	293,989,000	242,677,000	216,149,000	232,841,000	203,298,000	235,579,000	194,521,000	212,231,000	224,236,000	214,054,000	172,207,000	180,938,000	131,979,000	193,965,000	162,771,000	175,178,000	202,606,000	204,289,000	174,958,000	146,321,000	148,996,000	111,856,000	90,544,000	108,838,000	125,701,000	102,709,000	85,677,000	93,214,000	108,680,000	89,476,000	38,290,000	70,514,000	85,407,000	69,058,000		56,452,000	67,206,000	46,025,000		44,229,000	56,938,000	46,578,000		52,163,000	57,244,000	46,593,000		45,692,000	53,998,000	44,867,000		38,496,000	48,654,000	36,606,000		34,715,000	37,197,000	33,028,000	30,961,000	31,536,000	33,667,000	26,071,000	23,555,000	25,699,000	39,364,000	27,551,000	25,528,000	25,795,000	21,664,000	21,027,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	35,772,000	34,063,000	33,706,000	34,133,000	32,193,000	29,904,000	29,737,000	28,985,000	27,855,000	28,331,000	28,720,000	28,547,000	28,122,000	26,511,000	27,695,000	26,467,000	25,377,000	25,057,000	24,561,000	24,651,000	23,582,000	23,204,000	22,589,000	22,446,000	21,621,000	21,355,000	20,604,000	20,878,000	20,892,000	20,804,000	21,520,000	20,727,000	20,586,000	20,307,000		19,767,000	19,664,000	18,546,000		18,283,000	16,790,000	16,154,000		15,521,000	14,695,000	13,394,000		13,773,000	13,844,000	13,513,000		12,045,000	11,879,000	11,464,000		11,485,000	11,386,000	11,246,000	12,555,000	12,506,000	11,665,000	13,047,000	12,649,000	12,190,000	12,585,000	11,395,000	11,562,000	10,267,000	10,224,000	9,047,000
impairment charge				0	0	250,000									0	1,353,000			508,000								0									0	1,118,000	1,110,000
benefit from credit losses	1,470,000	2,890,000		1,337,000	2,213,000	1,530,000		1,607,000	1,532,000	2,325,000		1,754,000	1,266,000	2,092,000		951,000	582,000	186,000		-117,000	1,123,000	4,229,000
deferred income taxes	2,479,000	3,948,000	4,676,000	-6,849,000	-19,450,000	-2,571,000	-33,557,000	-1,817,000	-9,175,000	-3,757,000	1,825,000	-13,373,000	-18,489,000	-5,028,000	-7,426,000	-144,000	-1,051,000	5,244,000
share-based compensation expense	14,854,000	14,615,000	14,258,000	15,918,000	15,719,000	14,400,000	15,223,000	15,224,000	15,362,000	13,930,000	13,279,000	12,948,000	12,370,000	11,173,000	9,713,000	9,530,000	9,637,000	8,875,000	7,943,000	7,927,000	7,797,000	7,284,000	16,655,000	9,391,000	6,898,000	6,334,000	6,209,000	6,596,000	6,392,000	5,960,000	5,755,000	6,020,000	6,087,000	5,655,000		5,094,000	5,005,000	4,922,000		5,118,000	4,990,000	4,652,000		4,643,000	4,712,000	4,108,000		4,157,000	4,159,000	3,949,000		3,996,000	3,536,000	3,965,000		3,185,000	3,258,000	3,344,000	2,774,000	2,908,000	3,011,000	2,930,000	2,418,000	2,485,000	2,720,000	2,878,000	2,202,000	2,461,000	1,697,000	2,416,000
other	1,035,000	456,000	184,000	67,000	58,000	909,000	532,000	145,000	205,000	-362,000	613,000	832,000	965,000	235,000	217,000	1,102,000	967,000	333,000	891,000	-211,000	712,000	-13,000	-243,000	750,000	119,000	628,000	-1,485,000	772,000	522,000	1,091,000	453,000	310,000	-654,000	860,000		-380,000	954,000	586,000		-722,000
changes in assets and liabilities:
accounts receivable	-29,649,000	-45,240,000	27,807,000	26,894,000	-29,140,000	-53,841,000	686,000	6,601,000	-17,025,000	-44,133,000	-6,337,000	18,733,000	-16,263,000	-37,531,000	15,909,000	1,671,000	4,014,000	-54,735,000	11,687,000	-15,132,000	-19,215,000	-38,062,000	1,979,000	13,248,000	-4,278,000	-33,421,000	14,640,000	-169,000	-11,072,000	-21,800,000	-6,194,000	13,676,000	-12,971,000	-19,429,000		7,000,000	-2,143,000	-21,504,000		6,102,000	-5,688,000	-51,438,000		1,322,000	11,921,000	-21,707,000		11,366,000	-439,000	-23,722,000		8,032,000							-23,000	5,969,000	-1,029,000	-6,072,000	-5,266,000	4,495,000	4,048,000	-13,543,000	-11,257,000	3,792,000	-1,642,000	-16,428,000
inventories	-6,244,000	2,163,000	-3,245,000	-18,543,000	-3,801,000	-2,412,000	2,996,000	7,259,000	-15,019,000	-23,887,000	-22,110,000	-50,272,000	-30,495,000	-18,854,000	-6,028,000	-26,479,000	-12,493,000	-7,919,000	6,206,000	4,163,000	-14,820,000	-14,434,000	-724,000	-13,671,000	-8,390,000	-14,521,000	1,792,000	-10,590,000	-8,755,000	-8,070,000	3,904,000	-4,116,000	-13,481,000	-5,369,000		-2,717,000	-1,550,000	1,764,000		-11,215,000	-5,881,000	-10,142,000		-7,063,000	-7,775,000	2,200,000		-4,706,000	6,818,000	-8,472,000		-4,040,000	-6,589,000	897,000					14,368,000	-1,269,000	1,191,000	-8,067,000	-4,331,000	-7,177,000	-6,483,000	-477,000	-2,508,000	-4,524,000	4,885,000	-3,083,000
other assets and liabilities	-129,581,000	-10,325,000	-35,393,000	-64,055,000	40,199,000	-21,416,000	31,584,000	6,334,000	-18,929,000	-5,307,000	-15,283,000	7,163,000	-41,825,000	-52,904,000	-3,184,000	3,201,000	1,919,000	-57,081,000	29,659,000	26,039,000	69,421,000	-64,881,000	19,982,000	-8,948,000	3,779,000	-49,601,000	18,483,000	-2,433,000	-3,479,000	-52,302,000	58,152,000	10,692,000	17,105,000	-38,531,000		16,374,000	19,790,000	-27,516,000
accounts payable	-3,990,000	-8,123,000	5,739,000	-1,455,000	8,252,000	-4,450,000	6,242,000	-2,644,000	-7,482,000	3,327,000	7,397,000	2,805,000	-2,719,000	-4,016,000	10,596,000	-3,175,000	1,352,000	2,460,000	469,000	7,241,000	-4,974,000	-1,755,000	776,000	5,211,000	-4,729,000	699,000	1,170,000	-1,339,000	1,942,000	-1,939,000	4,931,000	-4,962,000	5,109,000	-3,687,000		-2,595,000	1,900,000	-1,801,000		151,000	1,340,000	-4,332,000		6,539,000	-1,520,000	1,857,000		-365,000	-1,105,000	3,654,000		1,303,000	6,454,000	548,000		1,799,000	-773,000	5,081,000	-2,288,000	-5,184,000	2,631,000	-4,315,000	-695,000	3,815,000	92,000	-7,539,000	10,599,000	-6,717,000	1,034,000	935,000
deferred revenue	5,608,000	838,000	-3,643,000	-209,000	-1,229,000	703,000	315,000	-1,492,000	-1,246,000	-609,000	-7,600,000	-1,075,000	-1,407,000	-937,000	-64,000	-2,450,000	-2,750,000	-2,287,000	-2,940,000	-3,738,000	-4,285,000	-2,410,000	-1,534,000	-3,977,000	-3,751,000	-3,098,000	-1,405,000	-3,062,000	-1,925,000	-1,327,000	1,272,000	381,000	1,429,000	469,000		710,000	2,451,000	637,000		-1,982,000	-1,859,000	1,153,000		3,427,000	4,912,000	3,227,000		1,686,000	1,495,000	869,000		2,649,000				12,000	2,034,000	524,000	1,623,000	-16,000	-477,000	-205,000	-278,000	-276,000	82,000	-333,000	-236,000	-110,000	716,000	167,000
net cash from operating activities	185,743,000	237,962,000	262,025,000	220,079,000	248,312,000	198,585,000	249,851,000	272,433,000	200,314,000	183,912,000	173,428,000	189,000,000	65,850,000	114,706,000	209,964,000	187,205,000	233,955,000	124,422,000	218,934,000	193,116,000	208,142,000	27,871,000	155,413,000	132,265,000	137,102,000	34,378,000	135,648,000	110,708,000	118,830,000	34,898,000	121,126,000	110,684,000	110,192,000	31,274,000	100,115,000	100,315,000			73,896,000	76,946,000			27,303,000	93,263,000	81,762,000	33,518,000	66,267,000	79,727,000	79,318,000	20,684,000	76,794,000	75,208,000	63,092,000	25,218,000	48,850,000	54,898,000	55,880,000	19,205,000	59,449,000	44,622,000			33,494,000	41,674,000			39,931,000	32,057,000
capex	-34,102,000	-30,026,000	-29,255,000	-28,089,000	-33,305,000	-30,273,000	-32,556,000	-34,094,000	-27,470,000	-39,511,000	-49,229,000	-37,685,000	-30,086,000	-31,838,000	-31,788,000	-45,017,000	-22,581,000	-20,163,000	-14,190,000	-19,210,000	-24,556,000	-49,002,000	-45,911,000	-37,071,000	-33,781,000	-38,206,000	-33,109,000	-31,265,000	-27,651,000	-23,726,000	-20,014,000	-15,804,000	-14,919,000	-23,647,000	0	-12,088,000			0	-20,644,000			0	-17,094,000	-14,112,000	-11,298,000	0	-16,908,000	-23,938,000	-19,761,000	0	-13,754,000	0	0	0	0	0	0	-13,803,000	-14,528,000			-24,255,000	-22,418,000			0	-15,488,000
free cash flows	151,641,000	207,936,000	232,770,000	191,990,000	215,007,000	168,312,000	217,295,000	238,339,000	172,844,000	144,401,000	124,199,000	151,315,000	35,764,000	82,868,000	178,176,000	142,188,000	211,374,000	104,259,000	204,744,000	173,906,000	183,586,000	-21,131,000	109,502,000	95,194,000	103,321,000	-3,828,000	102,539,000	79,443,000	91,179,000	11,172,000	101,112,000	94,880,000	95,273,000	7,627,000	100,115,000	88,227,000			73,896,000	56,302,000			27,303,000	76,169,000	67,650,000	22,220,000	66,267,000	62,819,000	55,380,000	923,000	76,794,000	61,454,000	63,092,000	25,218,000	48,850,000	54,898,000	55,880,000	19,205,000	45,646,000	30,094,000			9,239,000	19,256,000			39,931,000	16,569,000
cash flows from investing activities:
purchases of property and equipment	-34,102,000	-30,026,000	-29,255,000	-28,089,000	-33,305,000	-30,273,000	-32,556,000	-34,094,000	-27,470,000	-39,511,000	-49,229,000	-37,685,000	-30,086,000	-31,838,000	-31,788,000	-45,017,000	-22,581,000	-20,163,000	-14,190,000	-19,210,000	-24,556,000	-49,002,000	-45,911,000	-37,071,000	-33,781,000	-38,206,000	-33,109,000	-31,265,000	-27,651,000	-23,726,000	-20,014,000	-15,804,000	-14,919,000	-23,647,000		-12,088,000	-15,962,000	-21,906,000		-20,644,000	-23,856,000	-23,017,000		-17,094,000	-14,112,000	-11,298,000		-16,908,000	-23,938,000	-19,761,000		-13,754,000							-13,803,000	-14,528,000	-11,973,000	-9,114,000	-24,255,000	-22,418,000	-25,515,000	-17,049,000
acquisition of a business																								0
proceeds from net investment hedges	474,000	416,000	416,000	415,000	398,000	329,000	2,121,000
net cash used by investing activities	-33,628,000	-29,610,000	-39,843,000	-27,368,000	-32,907,000	-106,944,000	-30,435,000	-27,838,000	-27,470,000	-39,511,000	-49,229,000	-49,197,000	-55,086,000	-41,838,000	-44,040,000	-49,677,000	-174,663,000	-24,587,000		-19,460,000	-24,556,000	-49,670,000									-24,487,000	-41,487,000	-43,702,000	-29,012,000	-14,278,000	-22,946,000	-29,763,000	-23,799,000	-26,013,000	-54,806,000	-66,967,000	-160,620,000	-35,618,000	-23,449,000	-8,712,000	-12,634,000	-17,827,000	-27,374,000	-23,938,000	-16,920,000	-24,920,000	-16,349,000							-14,012,000	-20,702,000	-12,028,000	-6,879,000	-17,404,000	-22,684,000	-26,699,000	-24,808,000	-25,927,000			-56,041,000
cash flows from financing activities:
borrowings under credit facility	259,500,000	69,500,000
payments of senior notes			0
repurchases of common stock	-338,105,000	-400,890,000	-245,992,000	-220,757,000	-215,521,000	-154,764,000	-36,850,000				-74,020,000	-172,631,000	-306,765,000	-266,295,000	-244,756,000	-181,234,000	-188,525,000	-132,262,000	0	0	0	-182,815,000	-140,689,000	-85,975,000	-20,692,000	-54,302,000	-105,607,000	-73,828,000	-106,397,000	-83,487,000	-53,872,000	-57,895,000	-106,888,000	-63,910,000		-15,026,000	-23,056,000	-53,480,000		-88,960,000	-86,450,000	-133,647,000		-272,342,000	-126,347,000	-70,279,000		-76,575,000	-142,557,000	-63,778,000		-67,597,000
proceeds from exercises of stock options and employee stock purchase plans	17,330,000	7,193,000	13,255,000	4,996,000	5,362,000	20,879,000	11,330,000	12,618,000	10,290,000	12,796,000	12,490,000	4,878,000	6,726,000	11,653,000	9,137,000	10,057,000	9,777,000	17,594,000	12,098,000	18,617,000	10,403,000	10,210,000	7,367,000	9,086,000	8,102,000	11,551,000	3,606,000	12,690,000	7,354,000	14,551,000	7,308,000	8,144,000	10,644,000	12,526,000		11,261,000	11,794,000	5,760,000		3,571,000	3,325,000	12,325,000		3,654,000	3,743,000	10,964,000		5,314,000	3,462,000	12,958,000		6,713,000	7,198,000	12,169,000		5,609,000	9,963,000	6,483,000	3,262,000	6,216,000	3,607,000	3,281,000
shares withheld for statutory tax withholding payments on restricted stock	-970,000	-6,124,000	-45,000	-218,000	-79,000	-10,189,000	-68,000	-231,000	-79,000	-9,597,000	-54,000	-162,000	-52,000	-10,338,000	-61,000
net cash used by financing activities	-165,631,000	-330,321,000	-232,782,000	-290,979,000	-210,238,000	-144,074,000	-101,844,000	-43,038,000	-151,033,000	-146,081,000	-116,720,000	-148,829,000	-91,907,000	-13,480,000	-165,820,000	-221,726,000			398,000	-104,184,000			-74,389,000	-99,751,000	-109,488,000	-2,781,000	-117,806,000	-84,294,000			-78,058,000	-67,871,000			-76,612,000				-59,158,000				42,339,000	-76,268,000			-33,055,000	-40,331,000			-49,847,000	-36,530,000							-44,755,000	-22,404,000			-20,680,000				-12,521,000
net effect of changes in exchange rates on cash	14,140,000	-2,327,000	-9,770,000	5,314,000	-1,010,000	-4,066,000	4,664,000	-2,699,000	-340,000	501,000	5,891,000	-6,160,000	-9,113,000	776,000	-853,000	-2,733,000	1,896,000	-2,949,000	4,699,000	822,000	1,843,000	-4,033,000	1,217,000	-2,037,000	700,000	-569,000	-1,081,000	119,000	-5,141,000	1,335,000	75,000	1,718,000	2,477,000	1,932,000	-4,396,000	811,000	201,000	3,330,000	-881,000	-4,479,000	1,325,000	-1,913,000	-4,223,000	-5,859,000	344,000	1,221,000	-1,138,000	1,776,000	-1,414,000	-1,638,000	518,000	-228,000	996,000	1,269,000	429,000				-682,000	1,468,000
net decrease in cash and cash equivalents						-56,499,000				-1,179,000		-15,186,000						-32,765,000				-8,931,000		-6,849,000	-5,771,000	-7,178,000																																								-140,000		8,919,000	-4,349,000	-7,729,000
cash and cash equivalents at beginning of period	0	288,266,000	0	0	0	453,932,000	0	0	0	112,546,000	0	0	0	144,454,000	0	0	0	383,928,000	0	0	0	90,326,000	0	0	0	123,794,000	0	0	0	187,675,000	0	0	0	154,901,000		0	0	128,994,000		0	0	322,536,000		0	0	279,058,000		0	0	223,986,000		0	0	156,915,000		0	0	106,728,000	0	0	0	78,868,000	0	0	0	60,360,000	0	0	0	61,666,000
cash and cash equivalents at end of period	624,000	163,970,000	-20,370,000	-92,954,000	4,157,000	397,433,000	122,236,000	198,858,000	21,471,000	111,367,000	13,370,000	-15,186,000	-90,256,000	204,618,000	-749,000	-86,931,000	-119,029,000	351,163,000	208,341,000	70,294,000	23,898,000	81,395,000	-13,670,000	-6,849,000	-5,771,000	116,616,000	-23,083,000	-27,682,000	15,330,000	159,229,000	18,656,000	3,044,000	5,567,000	160,408,000		8,933,000	8,186,000	132,953,000		-22,002,000	-19,008,000	182,160,000		-12,313,000	18,845,000	286,203,000		13,798,000	22,649,000	228,364,000		22,101,000	5,939,000	153,459,000		15,537,000	11,621,000	106,354,000	0	2,984,000	17,449,000	86,295,000	-5,718,000	9,321,000	15,045,000	60,220,000	1,853,000	8,919,000	-4,349,000	53,937,000
supplemental cash flow information:
unpaid property and equipment, reflected in accounts payable and accrued liabilities	-2,242,000	10,702,000		2,083,000	-6,860,000	15,182,000		-4,120,000	2,995,000	12,453,000		9,321,000	-676,000	11,016,000		5,058,000	3,084,000	6,592,000		-4,962,000	-1,453,000	14,123,000		7,563,000
the accompanying notes are an integral part of these condensed consolidated financial statements.
net increase in cash and cash equivalents		-124,296,000	-20,370,000	-92,954,000			122,236,000	198,858,000						60,164,000	-749,000	-86,931,000			208,341,000	70,294,000							-23,083,000	-27,682,000	15,330,000	-28,446,000	18,656,000	3,044,000	5,567,000	5,507,000	4,829,000	8,933,000	8,186,000	3,959,000	-12,156,000	-22,002,000	-19,008,000	-140,376,000	29,801,000	-12,313,000	18,845,000	7,145,000	14,247,000	13,798,000	22,649,000	4,378,000	2,545,000	22,101,000			23,403,000	15,537,000			0	2,984,000	17,449,000	7,427,000	-5,718,000	9,321,000
impairment charges												0
benefit from uncollectible accounts																															485,000	571,000				590,000				360,000	939,000	509,000		890,000	337,000	451,000		446,000	136,000	644,000		314,000	82,000	601,000		910,000	211,000	385,000	252,000	20,000	408,000	246,000	-529,000	885,000	301,000	523,000	238,000	81,000	179,000	116,000
acquisitions of intangible assets																						-668,000									-2,000,000													0	0	-175,000			0	-659,000
equity investments
acquisitions of businesses, net of cash acquired																																										-383,000
(payments) borrowings on credit facility
debt issuance costs																			-30,000	-7,000			0	-12,000	-112,000	-30,000
payments of acquisition-related contingent consideration and holdbacks								-99,000				-2,914,000
the accompanying notes are an integral part of these consolidated financial statements.
repayments under credit facility
acquisitions of a business					0	-77,000,000
payments of acquisition-related holdbacks										-1,780,000
cash paid for income taxes					77,685,000	13,233,000		63,733,000	89,927,000	7,200,000		51,395,000	116,925,000	11,400,000		14,180,000	69,752,000	12,171,000		49,926,000	17,963,000	12,020,000
(repayments) borrowings on credit facility
purchase of minority interest
payment of acquisition-related contingent consideration and holdbacks
acquisition of intangible assets												0	0	-10,000,000						0
equity investment												0
acquisitions of a business, net of cash acquired																-4,660,000	-152,082,000	-4,424,000														0	-12,180,000	-2,349,000						-7,817,000				-6,355,000	0	-1,161,000
(repayments) borrowings under credit facility								-14,000,000	-167,500,000	-147,500,000
payment of senior debt												0	0	-75,000,000
proceeds from maturity of net investment hedges
borrowings (repayments) on credit facility
issuance of senior notes																			0	0			0	0	0	100,000,000
borrowings under revolving credit facility												22,000,000	211,000,000	326,500,000
acquisitions of intangible assets and equity investments
borrowings (repayments) on revolving credit facilities																																-17,750,000
acquisition of intangible assets and equity investments
repayments on revolving credit facilities																				-121,933,000				-22,013,000	-95,495,000	-52,024,000										-70,000,000
issuance of senior debt
payments of acquisition-related contingent considerations and holdbacks																0
acquisition of intangible assets and equity investment
shares withheld for statutory tax withholding on restricted stock																	31,000	-14,983,000	-11,574,000	-361,000	-64,000	-8,604,000	-204,000	-277,000	-169,000	-7,403,000	-265,000	-390,000	-165,000	-8,555,000	-244,000	-370,000	-156,000	-7,303,000
borrowings on revolving credit facilities																																		60,000,000				49,000,000				500,000		-9,000,000	69,000,000	38,000,000			107,500,000	48,000,000		21,417,000					-23,424,000	38,523,000			-11,237,000	15,019,000	-12,549,000	6,151,000	18,006,000	67,942,000
net cash (used) provided by financing activities																		-129,651,000												-324,991,000																-14,960,000
(benefit of) benefit from deferred income taxes																																														-835,000
purchases of marketable securities
proceeds from the sale and maturities of marketable securities																											0	0	0	284,125,000	61,943,000	68,913,000	68,427,000	87,476,000		44,162,000	37,929,000	70,186,000		14,672,000	6,811,000	3,228,000
net cash (used) provided by investing activities																							-95,911,000	-37,326,000	-34,085,000	-38,206,000
repayment on revolving credit facilities
payment of acquisition-related contingent consideration																			-96,000	-500,000			-120,000	-560,000	-1,122,000	-573,000	0	-266,000								-916,000	-633,000	-2,084,000
acquisitions of a business and equity investment, net of cash acquired
benefit of deferred income taxes																					-195,000	2,853,000		-1,023,000	132,000	3,294,000			5,633,000	3,005,000			750,000	1,941,000				2,520,000		-2,594,000				-1,504,000																						-999,000	-864,000	-3,864,000	-2,507,000	-1,839,000
borrowing (repayments) on revolving credit facilities																						198,110,000
net cash provided (used) by financing activities																						16,901,000												1,313,000							-33,532,000	36,801,000								2,252,000																			-47,981,000	49,289,000
benefit of (benefit from) deferred income taxes																											-11,641,000
acquisitions of intangible assets and equity investment
acquisitions of businesses
(repayment) borrowings on revolving credit facilities
purchase of marketable securities																												0	0	-87,000		-94,276,000	-85,030,000	-90,492,000		-55,020,000	-51,730,000	-72,079,000		-41,017,000	-49,922,000	-140,448,000
amortization on marketable securities																																										91,000
tax benefit from share-based compensation arrangements																																				-5,434,000	-2,728,000	-2,063,000		-1,298,000	-1,033,000	-7,713,000		-1,621,000	-1,213,000	-6,747,000		-1,608,000	-520,000	-5,310,000
net cash provided (used) by investing activities																											-39,844,000	-54,215,000	-27,651,000	260,312,000
debt issue costs																																				0	0	-57,000		-72,000	-37,000	-90,000		-201,000	-1,017,000	-139,000
(repayments) borrowings on revolving credit facilities																												-22,500,000	29,500,000	-247,500,000										44,500,000
benefit from deferred income taxes																																																		1,169,000				2,501,000				769,000
(benefit from) benefit of deferred income taxes
adjustments to reconcile net income to net cash provided (used) by operating activities:
benefit from (benefit of) deferred income taxes																																				4,727,000						565,000																	-435,000			1,465,000
issuance of long-term debt
net cash provided (used) by operating activities																																						23,226,000																								12,624,000
net cash from financing activities																																						1,202,000																								3,285,000				24,768,000
other assets																																								8,249,000	17,313,000	15,479,000		-425,000	-4,262,000	1,312,000		310,000	-1,894,000	6,301,000		-4,237,000	4,631,000	2,662,000				1,441,000	-4,716,000	-358,000	-2,947,000	179,000	-3,365,000	-295,000	84,000	-1,540,000	-7,181,000	103,000	-2,192,000	712,000
accrued liabilities																																								3,086,000	-1,364,000	-26,225,000		19,560,000	6,887,000	-10,231,000		8,418,000	5,232,000	-16,919,000		21,835,000				9,015,000			5,946,000	-1,818,000	8,971,000	-12,394,000	2,067,000	3,924,000	17,670,000	-18,190,000	13,772,000	8,212,000	21,393,000	-11,453,000
proceeds from sale of equity investment																																												0
issuance of long term debt																																										150,000,000
payment of notes payable																																												0	-1,141,000	-253,000		-378,000	-242,000	-238,000		-218,000
adjustments to reconcile net income to net cash (used) provided by operating activities:
gain on disposal of property and equipment																																										-33,000
increase in deferred compensation liability																																										58,000			93,000	-86,000		137,000	-25,000	114,000		-391,000	-17,000	88,000				101,000	114,000
net cash (used) provided by operating activities																																										-14,644,000
acquisition of intangible asset
proceeds from disposition of pharmaceutical product lines																																																0	0	3,500,000		0	0	3,000,000					2,000,000	0	0	1,377,000
loss on disposal of property and equipment																																																149,000	44,000	27,000		155,000	16,000	310,000		58,000	350,000	1,092,000	150,000	147,000
impairment of property and equipment
gain on sale of equity investment
(gain) loss on disposal of property and equipment																																														-18,000
proceeds from sale of property and equipment																																																				5,000	136,000	82,000		22,000	37,000	27,000	23,000	980,000	30,000	1,046,000
acquisition of a business, net of cash acquired
borrowings (payments) on revolving credit facilities																																																											-24,032,000									-8,796,000	5,316,000	74,511,000
acquisitions of intangible asset
(payments) borrowings on revolving credit facilities
tax benefit from exercises of stock options and vesting of restricted stock units																																																				-3,155,000	-17,872,000	7,018,000		3,921,000	6,054,000	3,318,000	-1,343,000	-2,496,000	-1,194,000	-161,000
changes in assets and liabilities, net of acquisitions:
purchase of treasury stock																																																												-18,241,000	-24,739,000	-14,986,000		-20,098,000	-50,976,000	-51,355,000	-18,703,000	-7,151,000	-57,714,000	-34,819,000
write-down of marketable securities																																																											0	0
payment of other notes payable																																																											-195,000	-295,000	-246,000	-190,000		-185,000	-180,000	-177,000	-185,000	-170,000	-719,000	-1,323,000
acquisitions of equipment leased to customers																																																											-498,000	-474,000	-85,000	-188,000	-174,000	-131,000	-203,000	-226,000	-366,000	-215,000	-287,000	-238,000
supplemental disclosures of cash flow information:
interest paid																																																										373,000	550,000	489,000	629,000	1,105,000	1,461,000	1,463,000	970,000	1,182,000	1,432,000	1,270,000	901,000	539,000
income taxes paid																																																										3,790,000	11,215,000	11,842,000	19,337,000	3,337,000	6,313,000	12,961,000	14,930,000	15,343,000	5,816,000	12,835,000	3,197,000	14,814,000
(gain) loss on disposition of pharmaceutical product lines and related restructuring
write-down of equine digital radiography intangible assets
navigator® inventory write-down and royalty license impairment																																																																			0	0
sales and maturities of short- and long-term investments																																																																			0	0	0	35,000,000
acquisitions of intangible assets and businesses, net of cash acquired																																																											-1,734,000				0	-135,000	-981,000	-7,533,000	-2,146,000	-2,231,000	-5,196,000	-80,311,000
purchases of treasury stock
supplemental disclosure of non-cash information:
market value of common shares received from employees in connection with share-based compensation – see note 16
consideration payable for acquisitions
note receivable on disposition of pharmaceutical product lines
increase in deferred compensation expense
decrease in deferred compensation expense																																																														-100,000
net effect of exchange rates on cash																																																														-1,603,000	-1,128,000	-3,927,000	-49,000	2,689,000	370,000	1,770,000	335,000	410,000
loss on disposition of pharmaceutical product lines and related restructuring
write-down of long-term assets
partner’s interest in loss of subsidiary
purchases of short- and long-term investments
purchase of land and buildings
payments of other notes payable
market value of common shares received from employees in connection with share-based compensation — see note 15
reduction (increase) in deferred compensation expense
tax benefit from exercises of stock options																																																																-2,708,000	-814,000	-2,384,000	-1,723,000	-3,474,000	-1,066,000	-3,004,000
sales and maturities of short-term investments
proceeds from exercises of stock options																																																																5,682,000	3,200,000	5,974,000
reduction in deferred compensation expense																																																																	100,000	-131,000
adjustments to reconcile net income to net cash used by operating activities:
net cash used by operating activities																																																																		-2,789,000				-1,387,000
noncash (gain) on investments
net proceeds from sale of land and buildings
market value of common shares received from employees in connection with share-based compensation – see note 15
receivable for purchase price adjustment of business acquisitions
noncash loss on investments
purchases of property, plant and equipment																																																																				-15,488,000	-15,743,000	-10,492,000
proceeds from exercises of options																																																																				5,669,000	4,070,000	7,916,000
excess tax benefit from exercises of stock options																																																																						3,004,000
changes in assets and liabilities, net of acquisitions and disposals
purchase of short- and long-term investments
purchase of property and equipment
acquisition of equipment leased to customers
acquisition(s) of business(es), net of cash acquired
proceeds from the exercise of stock options
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosure of cash flow information:
value of mature shares exchanged in stock option exercises
payable for treasury stock

We provide you with 20 years of cash flow statements for IDEXX Laboratories stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDEXX Laboratories stock. Explore the full financial landscape of IDEXX Laboratories stock with our expertly curated income statements.

The information provided in this report about IDEXX Laboratories stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.